Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

Angiogenesis inhibitor

DRUG CLASS:

Angiogenesis inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Glioblastoma	No biomarker	Glioblastoma	VB-111 Sensitive: B - Late Trials VB-111 Sensitive : B	VB-111 Sensitive: B - Late Trials VB-111 Sensitive : B
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	VB-111 Sensitive: B - Late Trials VB-111 Sensitive : B	VB-111 Sensitive: B - Late Trials VB-111 Sensitive : B
EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	SIBP-04 (bevacizumab biosimilar) Sensitive: B - Late Trials SIBP-04 (bevacizumab biosimilar) Sensitive : B	SIBP-04 (bevacizumab biosimilar) Sensitive: B - Late Trials SIBP-04 (bevacizumab biosimilar) Sensitive : B
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	Angiogenesis inhibitor Sensitive: C3 – Early Trials Angiogenesis inhibitor Sensitive : C3	Angiogenesis inhibitor Sensitive: C3 – Early Trials Angiogenesis inhibitor Sensitive : C3
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	PD1 inhibitor + Angiogenesis inhibitor Sensitive: C3 – Early Trials PD1 inhibitor + Angiogenesis inhibitor Sensitive : C3	PD1 inhibitor + Angiogenesis inhibitor Sensitive: C3 – Early Trials PD1 inhibitor + Angiogenesis inhibitor Sensitive : C3
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	EGFR inhibitor + Angiogenesis inhibitor Sensitive: C3 – Early Trials EGFR inhibitor + Angiogenesis inhibitor Sensitive : C3	EGFR inhibitor + Angiogenesis inhibitor Sensitive: C3 – Early Trials EGFR inhibitor + Angiogenesis inhibitor Sensitive : C3
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	Angiogenesis inhibitor Sensitive: C3 – Early Trials Angiogenesis inhibitor Sensitive : C3	Angiogenesis inhibitor Sensitive: C3 – Early Trials Angiogenesis inhibitor Sensitive : C3
TP53 mutation	Hepatocellular Cancer	TP53 mutation	Hepatocellular Cancer	PD1 inhibitor + Angiogenesis inhibitor Resistant: C3 – Early Trials PD1 inhibitor + Angiogenesis inhibitor Resistant : C3	PD1 inhibitor + Angiogenesis inhibitor Resistant: C3 – Early Trials PD1 inhibitor + Angiogenesis inhibitor Resistant : C3
ARID1A mutation	Hepatocellular Cancer	ARID1A mutation	Hepatocellular Cancer	PD1 inhibitor + Angiogenesis inhibitor Resistant: C3 – Early Trials PD1 inhibitor + Angiogenesis inhibitor Resistant : C3	PD1 inhibitor + Angiogenesis inhibitor Resistant: C3 – Early Trials PD1 inhibitor + Angiogenesis inhibitor Resistant : C3
PD-L1 expression	Hepatocellular Cancer	PD-L1 expression	Hepatocellular Cancer	PD1 inhibitor + Angiogenesis inhibitor Sensitive: C3 – Early Trials PD1 inhibitor + Angiogenesis inhibitor Sensitive : C3	PD1 inhibitor + Angiogenesis inhibitor Sensitive: C3 – Early Trials PD1 inhibitor + Angiogenesis inhibitor Sensitive : C3
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	Angiogenesis inhibitor Sensitive: C3 – Early Trials Angiogenesis inhibitor Sensitive : C3	Angiogenesis inhibitor Sensitive: C3 – Early Trials Angiogenesis inhibitor Sensitive : C3
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	Angiogenesis inhibitor Sensitive: C3 – Early Trials Angiogenesis inhibitor Sensitive : C3	Angiogenesis inhibitor Sensitive: C3 – Early Trials Angiogenesis inhibitor Sensitive : C3